Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is poised for long-term success with its innovative technology platform, the Antibody Biopolymer Conjugate (ABC) platform, and its promising pipeline of investigational medicines targeting retinal diseases. With the recent positive results from the Phase 3 GLOW2 study for Zenkuda and the upcoming data readout in September for the DAYBREAK study, Kodiak's potential for market disruption and commercial success is clearly evident. While competition may pose a challenge, Kodiak's innovative approach and high-strength bispecific protein, KSI-101, set it apart from its competitors and position it for a strong future in the retinal medicine market.

Bears say

Kodiak Sciences is facing significant financial and clinical risks in bringing their investigational medicines to market, and the potential for manufacturing difficulties with their proprietary ABC platform could impede development. The company's tarcocimab tedromer, with its potential limitations and inconsistent efficacy, will need to navigate regulatory hurdles and may require additional capital to continue development. While the successful Phase 3 trial of tarcocimab in DR is a positive sign, the overall outlook for Kodiak's stock is uncertain given the various risks and uncertainties.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.